Early Diagnosis, Pathogenesis and Progression of Open Angle Glaucoma - Full Text View

Early Diagnosis, Pathogenesis and Progression of Open Angle Glaucoma

This study is currently recruiting participants.
Verified by University of Erlangen-Nürnberg, June 2007

Sponsors and Collaborators:	University of Erlangen-Nürnberg German Research Foundation
Information provided by:	University of Erlangen-Nürnberg
ClinicalTrials.gov Identifier:	NCT00494923

Purpose

The Erlangen Glaucoma Registry is a clinical registry for cross sectional and longitudinal observation of patients with open angle glaucoma (OAG) or glaucoma suspect, founded in 1991. Primary aim is the evaluation of diagnostic and prognostic validity of morphometrical, sensory and hemodynamical diagnostic procedures. No therapeutic studies are performed.

Condition

Primary Open Angle Glaucoma
Persons at Risk for Glaucoma

Genetics Home Reference related topics:

early-onset glaucoma

MedlinePlus related topics:

Glaucoma

U.S. FDA Resources

Study Type:	Observational
Study Design:	Natural History, Longitudinal, Defined Population, Prospective Study

Official Title:	Glaucoma Including Pseudoexfoliation Syndrome (SFB 539)

Further study details as provided by University of Erlangen-Nürnberg:

Study Start Date:

January 1999

Detailed Description:

Purpose: Detection of onset and progression of structural and functional damage due to glaucoma. Determination of rate and amount of progressive change due to glaucoma. Characterisation of the relationship between structural und functional change over time. Evaluation of predictive factors for the development and progression of glaucoma.

Eligibility

Ages Eligible for Study:	18 Years to 65 Years
Genders Eligible for Study:	Both

Criteria

Participants:

Patients: Primary open angle glaucoma, secondary open angle glaucoma due to PEX or MDS, glaucoma suspects including ocular hypertension
Healthy volunteers (for cross sectional analysis only)

Inclusion Criteria:

Open anterior chamber angle
Best corrected visual acuity 0.7 or better
Age between 18 and 65 years

Exclusion Criteria:

Any eye disease other than glaucoma
Systemic diseases with potentially ocular involvement (e.g. diabetes mellitus)
Myopic or hyperopic refractive error exceeding 8.0 diopters

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00494923

Contacts


Contact: Anselm G Juenemann, Prof.	**49-9131-8533001	anselm.juenemann@augen.imed.uni-erlangen.de

Locations


Germany
	University Eye Hospital	Recruiting
	Erlangen, Germany, 91054
	Contact: Robert Laemmer, MD **49-9131-8533001 robert.laemmer@augen.imed.uni-erlangen.de
	Principal Investigator: Christian Y Mardin, Prof.
	Principal Investigator: Folkert K Horn, PhD
	Principal Investigator: Georg Michelson, Prof.

Sponsors and Collaborators

University of Erlangen-Nürnberg

German Research Foundation

Investigators


Study Chair:	Anselm G Juenemann, Prof.	University Erlangen-Nuremberg

More Information

Study ID Numbers:	DFG-SFB539-R
First Received:	June 29, 2007
Last Updated:	June 29, 2007
ClinicalTrials.gov Identifier:	NCT00494923
Health Authority:	Germany: Ethics Commission

Study placed in the following topic categories:

Glaucoma

Eye Diseases

Glaucoma, Open-Angle

Disease Progression

Exfoliation Syndrome

Hypertension

Ocular Hypertension

Additional relevant MeSH terms:

Uveal Diseases

Iris Diseases

ClinicalTrials.gov processed this record on November 06, 2008